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The intestinal microbiota has been linked to inflam-
matory bowel diseases (IBD), and oral treatment
with specific bacteria can ameliorate IBD. One
bacterial mixture, VSL#3, containing Lactobacillus,
Bifidobacterium, and Streptococcus, was clinically
shown to reduce inflammation in IBD patients and
normalize intestinal levels of IP-10, a lymphocyte-
recruiting chemokine, in a murine colitis model. We
identified Lactobacillus paracasei prtP-encoded
lactocepin as a protease that selectively degrades
secreted, cell-associated, and tissue-distributed
IP-10, resulting in significantly reduced lymphocyte
recruitment after intraperitoneal injection in an ileitis
model. A human Lactobacillus casei isolate was
also found to encode lactocepin and degrade
IP-10. L. casei feeding studies in a murine colitis
model (T cell transferred Rag2/ mice) revealed
that a prtP-disruption mutant was significantly less
potent in reducing IP-10 levels, T cell infiltration
and inflammation in cecal tissue compared to the
isogenic wild-type strain. Thus, lactocepin-based
therapies may be effective treatments for chemo-
kine-mediated diseases like IBD.
INTRODUCTION
Inflammatory bowel diseases (IBD), comprising the idiopathic
pathologies ulcerative colitis (UC) and Crohn’s disease (CD),Cell Hare immune-mediated chronic disorders of the gastrointestinal
tract. Genetic susceptibility (Anderson et al., 2011; Franke
et al., 2010) and environmental factors are crucial parameters
in the pathogenesis of IBD. Clinical data and experimental
studies using gnotobiotic IBDmodels revealed that the intestinal
microbiota plays a major role in the progression of the chronic
intestinal inflammation. In addition, the intestinal microbiota in
IBD patients has been shown to differ from the one in healthy
individuals with regard to bacterial species abundance and
diversity (Manichanh et al., 2006; Qin et al., 2010). However,
although it is still not clear whether the observed changes of
the intestinal microbiota are cause or consequence of the
chronic inflammation, the normalization of the intestinal micro-
biota and host-microbial interactions is an important goal in
order to re-establish intestinal homeostasis. In this context, pro-
biotics are hypothesized to exert beneficial effects by either
modulating the intestinal microbiota toward a more protective
one or by direct microbe-host interactions, resulting in strength-
ening of the intestinal barrier or regulation of the mucosal
immune system (Gareau et al., 2010). There are several clinical
studies reporting effective use of specific bacterial strains,
mainly E. coli Nissle and VSL#3, in the prevention or reduction
of acute inflammation in pouchitis and UC patients (Gionchetti
et al., 2007; Kruis et al., 2004; Miele et al., 2009; Sood et al.,
2009; Tursi et al., 2010), but the underlying mechanisms are
far from being understood with regard to active bacterial
structures and the way microbes interact with host target
structures (Ho¨rmannsperger and Haller, 2010; Lebeer et al.,
2010). However, knowledge of strain-specific protective mecha-
nisms is crucial for the development of targeted therapies. In
infectious diseases, a recent study showed that bifidobacteria-
derived acetate protects mice from enterohaemorrhagic
E. coli O157:H7-induced death by inducing the expression ofost & Microbe 11, 387–396, April 19, 2012 ª2012 Elsevier Inc. 387
A B
C
Figure 1. L.p Expresses a Cell Surface-Associated
and Secreted Protein that Mediates Loss of IEC-
Associated IP-10
(A)Mode-K cells were stimulatedwith fixed (f) L.p or fBL23
with/without TNF (10 ng/ml) activation (A, upper panel).
Mode-K cells were stimulated for 24 hr with CM L.p (13)
or CM BL23 (13) with/without TNF activation. Secreted
IP-10 was measured by ELISA. IEC-associated IP-10 was
analyzed by western blot (A, lower panel).
(B) shows the level of secreted and IEC-associated IP-10
in unstimulated Mode-K cells after 24 hr (lane 1), Mode-K
cells that were stimulated with TNF (10 ng/ml) for 12 hr
(lane 2) or 24 hr (lane 3) and Mode-K cells that were
stimulated with TNF and CM L.p (13) according to the
following schedule (t = timeline): preincubation with CM
L.p (t:-1-0 hr) prior to TNF (t:0-24 hr) (lane 4); CM L.p (t:12-
24 hr) stimulation post TNF (t:0-24 hr) (lane 5). IP-10
concentrations in the cell culture supernatants were
determined by ELISA, IEC-associated IP-10was analyzed
by western blot.
(C) Mode-K cells were stimulated with TNF or TNF and
Heparin (10 mg/ml). Secreted (supern.) or IEC-associated
IP-10 was analyzed by western blot. Data are represented
as mean ± SD. (*) indicates p values% 0.05, (**) indicates
p values% 0.01. See also Figure S1.
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Protective Chemokine Degradation via Lactocepinanti-inflammatory genes in the colonic epithelium and reducing
the translocation of Shiga toxin (Fukuda et al., 2011). With regard
to IBD, Lactobacillus rhamnosus GG was found to express
a soluble protein, p40, that reduces DSS- and oxazolone-
induced colitis via epidermal growth factor receptor (EGFR)
activation, resulting in decreased IEC apoptosis and increased
epithelial barrier functions (Yan et al., 2011). Investigating the
protective effects of the clinically effective mixture VSL#3, we
previously showed that cell surface proteins of the VSL#3-
derived single strain Lactobacillus paracasei (L.p) mediate loss
of IEC-derived IP-10, a major proinflammatory chemokine in
IBD (Ho¨rmannsperger et al., 2009). Since VSL#3 feeding of
IL-10/ mice was associated with reduced IP-10 levels and
abrogated cecal tissue inflammation (Ho¨rmannsperger et al.,
2009), we aimed to unravel the microbial structure-function rela-
tionship underlying this potent anti-inflammatory effect. We
found that VSL#3-derived L.p expresses a prtP-encoded lacto-
cepin that selectively degrades IP-10 and other proinflammatory
chemokines in the diseased tissue environment. This unex-
pected finding suggests that prtP-encoded lactocepin could
be applied as an anti-inflammatory therapy in an array of chemo-
kine-mediated chronic inflammatory diseases such as IBD.
RESULTS
L.p Secretes a Serine Protease that Selectively Targets
an Array of Proinflammatory Chemokines
We previously reported that a single strain of VSL#3, L.p (classi-
fied as L. casei VSL#3 until 2009), expresses cell surface proteins
that mediate selective posttranslational loss of IP-10 in IEC
(Ho¨rmannsperger et al., 2009). Subsequent studies revealed
that secreted components of L.p mediate analogous effects
(Figure 1A), whereas other lactobacilli, such as L. casei BL23
(BL23), did not show the same effect. Protein precipitation anal-
ysis and size exclusion studies revealed that the active secreted388 Cell Host & Microbe 11, 387–396, April 19, 2012 ª2012 Elseviercomponent of L.p is a protein or protein complex that exceeds
a molecular mass of 100 kDa (Figures S1A and S1B). Kinetic
analysis showed that preincubation of IEC with conditioned
media (CM) of L.p prior to TNF-activation does not result in
loss of IP-10. In contrast, CM L.p applied to TNF-activated cells
12 hr after initial TNF stimulation does prevent additional IP-10
secretion and even results in complete loss of the already
produced, secreted, and cell-bound IP-10 in IEC (Figure 1B). In
addition, IEC-associated IP-10 was antagonized in the presence
of heparin (Figure 1C), suggesting that the majority of detectable
IP-10 is located at the epithelial surface, as it has already been
reported for endothelial cells (Luster et al., 1995). We therefore
raised the hypothesis that CM L.p contains a protease that
directly degrades cell surface-bound IP-10 independent of
cellular signal transduction processes. Indeed, incubation of
recombinant murine IP-10 (mIP-10) with CM L.p in a cell-free
system resulted in the loss of IP-10. This effect was reversed
by the serine protease inhibitor PMSF, whereas Marimastat,
a matrix metalloproteinase inhibitor, showed no effect (Fig-
ure 2A). This result indicates that L.p secretes a serine protease
that selectively degrades secreted and cell surface-associated
IP-10. Aiming to characterize this serine protease in more detail,
we screened for cleavage sites using MALDI-TOF analysis. The
bacterial protease was found to cleave mIP-10 at various sites,
resulting in complete degradation of the chemokine (Figure 2B).
In contrast to the low cleavage site specificity, we found the
bacterial protease to be highly selective for an array of proinflam-
matory chemokines. In contrast, additionally tested cytokines
and the adherence junction protein E-Cadherin were unaffected
(Figures 2B, 2C, and Table 1), although these proteins also
contain several potential cleavage sites (Figure 2C).We therefore
assume that the three-dimensional protein structure determines
whether a protein is cleaved or not, perhaps via the accessibility
of cleavage sites. No adverse effects of the bacterial protease on
IEC viability and barrier function were observed (Figure S2).Inc.
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Figure 2. Cleavage Site Analysis
(A) CM L.p, PMSF- (2 mM) or Marimastat (Marim.)-pretreated (0.5 mM) CM L.p was coincubated with recombinant murine IP-10 (mIP-10). IP-10 concentrations
were analyzed by ELISA.
(B) CM L.p was coincubated with mIP-10 or mRANTES (1 hr, 24 hr). The relative molecular mass of mIP-10 andmRANTES before and after coincubation with CM
L.p was determined by MALDI-TOF MS (respective mass [Da] is indicated by an arrow).
(C) CM L.p was coincubated with mRANTES, hI-TAC, mIP-10, or mIL-10 for 0.5 hr, 1 hr, or 24 hr and subjected to MALDI-TOF-MS. After 24 hr, the chemokine
suspension and the respective chemokine/CM L.p suspension were subjected to SDS gel electrophoresis and Flamingo staining (C, left panel). Amino acid
sequences (one-letter code) of mIP-10, hI-TAC, mRANTES, and mIL-10 are displayed, and all detected cleavage sites of the serine protease in CM L.p are
indicated (;). Sites that were targeted in mIP-10 (7) or in hI-TAC ( ) but that are not targeted in mRANTES or mIL-10 are indicated. Actual and theoretical
cleavage sites are highlighted in red. (*) indicates p values% 0.05; (**) indicates p values% 0.01. See also Figure S2.
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Protective Chemokine Degradation via LactocepinThe Serine Protease in CM L.p Effectively Degrades
IP-10 in Inflamed Ileal Tissue and Mediates
Anti-Inflammatory Effects In Vivo
To address the physiological relevance of CM L.p-mediated
IP-10 degradation, we performed ex vivo tissue culture experi-
ments using ileal specimen from healthy wild-type mice (Fig-
ure S3) or inflamed TNFDARE/+ mice, an experimental model for
Th1-mediated ileitis (Kontoyiannis et al., 2002). These experi-
ments showed that CM L.p selectively degrades tissue-derived
IP-10 in a PMSF-sensitive manner, whereas tissue-derived
TNF is unaffected by the bacterial protease (Figure 3A). CM
L.p was also found to be highly potent to degrade tissue-distrib-
uted IP-10 in inflamed ileal tissue explants of TNFDARE/+ mice
(Figure 3B).Cell HIn order to analyze whether the ex vivo observed CM L.p-
mediated degradation of IP-10 in the tissue can be transferred
to the in vivo situation, inflamed TNFDARE/+ mice were treated
with intraperitoneal (i.p.) injections of CM L.p or PBS. Treatment
of TNFDARE/+ mice with CM L.p resulted in selective loss of IP-10
protein in the ileal tissue (Figure 3C), correlating with reduced
activation of IBD-relevant proinflammatory signaling pathways
such as NFlB (represented by p-RelA), p38 MAPK, and PI3P/
Akt (Figure 3D). In addition, the injection of CM L.p reduced
the infiltration of mononuclear cells (MNC), which was most
prominent in the ileal muscularis (Figure 3E, upper panel, 117 ±
32 [PBS] versus 44 ± 12 [CM L.p] MNC/roi, p value < 0.01).
Furthermore, myeloperoxidase (MPO)-positive cells were
reduced in ileal tissue (Figure S3B). Consistent with the factost & Microbe 11, 387–396, April 19, 2012 ª2012 Elsevier Inc. 389
Table 1. Substrate Specificity of the Bacterial Protease in CML.p
Protein Species Degradation
MIG/CXCL9 h +
IP-10 /CXCL10 m/h +
I-TAC/CXCL11 m/h +
SDF-1a/CXCL12 m/h +
Fractalkine/CX3CL1 h +
Eotaxin/CCL11 h +
GROb/CXCL2 h -
MIP-2/CXCL2 m -
GCP-2/CXCL6 h -
IL-8/CXCL8 h -
RANTES/CCL5 m -
MIP-3a/CCL20 h -
TNF m/h -
IFNg m -
IL-6 m -
IL-10 m -
E-Cadherin m/h -
Murine, m; human, h; + indicates degradation of the respective protein; –
indicates no degradation of the respective protein. CM L.p was coincu-
bated with the respective protein (24 hr), and degradation was analyzed
by MALDI-TOF or SDS-PAGE/flamingo staining.
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Protective Chemokine Degradation via Lactocepinthat IP-10 mainly recruits activated T cells (Dufour et al., 2002),
the injection of CM L.p resulted in significantly reduced T cell
infiltration (CD3+ cells) into the ileal tissue of TNFDARE/+ mice
(Figure 3E, middle and lower panels). In order to analyze whether
the reduced recruitment of immune cells was due to the proteo-
lytic activity of the chemokine-degrading protease in CM L.p,
inflamed TNFDARE/+ mice were treated with i.p injections of CM
L.p or PMSF-inactivated CM L.p. Injection of CM L.p reduced
the number of tissue-infiltrating MNC (Figure 3F, upper panel,
86 ± 16 [PMSF-inactivated CM L.p] versus 54 ± 21 [CM L.p]
MNC/roi, p value = 0.02), CD3+ T cells (Figure 3F, middle and
lower panels), as well as MPO-positive cells (Figure S3C),
compared to TNFDARE/+ mice treated with PMSF-inactivated
CM L.p, thus strongly supporting the involvement of a serine
protease in the reduction of proinflammatory mechanisms.
Identification of prtP-Encoded Lactocepin as Active
Bacterial Protease
In order to identify the protective serine protease in CM L.p,
chromatographic fractionation of CM L.p was performed.
However, size exclusion, ion exchange, and hydrophobic inter-
action chromatography all resulted in the generation of several
distinct active fractions containing more than one protein
(Figures S4A and S4B). In order to identify the active protease
under these conditions, an array of highly active and inactive
fractions were subjected to LC-MS/MS analysis. PrtP-encoded
lactocepin, a caseinolytic serine protease, was found to be
exclusively present in active fractions, indicating that this might
be the protective protease (Figure S4C). However, this finding
raised the question why the lactocepin-encoding strain BL23
was inactive with regard to the degradation of IP-10 (Figure 4A).
Subsequent LC-MS/MS analysis of CM L.p and CM BL23 re-390 Cell Host & Microbe 11, 387–396, April 19, 2012 ª2012 Elseviervealed that BL23 does not produce prtP-encoded lactocepin
(Figure 4A and Table S1) and that prtP-encoded lactocepin is
the only detectable serine protease in CM L.p (Table S1), con-
firming the assumption that prtP-encoded lactocepin is the
protective bacterial protease. In order to prove this hypothesis,
we immunoprecipitated lactocepin from CM L.p (confirmed by
LC-MS/MS) and subsequently analyzed the IP-10-degrading
capacity of lactocepin-coated beads. Consistent with our
hypothesis, lactocepin-coated beads showed a high IP-10-de-
grading capacity (Figure 4B), which was found to be abrogated
by preincubation of lactocepin-coated beads with PMSF (Fig-
ure 4C). These results clearly identified prtP-encoded lactocepin
to be the physiologically relevant chemokine-degrading
protease in CM L.p.
PrtP-Encoded Lactocepin Mediates Reduced Cecal
Inflammation
In order to analyze the physiological relevance of orally applied
prtP-encoded lactocepin in the context of IBD, we tried to
generate aprtP-disruptionmutant of L.p to be applied in amouse
model of experimental colitis. However, the transformation effi-
cacy of L.p was insufficient. We thus screened fecal lactobacilli
isolates from healthy human volunteers for strains showing anal-
ogous anti-IP-10 activity. As shown in Figure 4, CM L. casei
BFLM 218 (L.c) tested positive for the direct, PMSF-sensitive
degradation of IP-10 (Figure 4D) and for the presence of prtP-en-
coded lactocepin (Figure 4F). Sequence analysis revealed that
L.c-encoded prtP is 99% homologous to L.p-derived prtP. We
then generated a prtP disruption mutant of L.c (L.c prtPdis) (Fig-
ure 4E) and confirmed the absence of lactocepin in CM L.c
prtPdis via LC-MS/MS analysis (Figure 4F). As expected, CM
L.c prtPdis and fixed L.c prtPdis failed to degrademIP-10, proving
that prtP-encoded lactocepin is the chemokine-degrading
protease of L.c (Figures 4F and 4G).
L.c and L.c prtPdis were subsequently fed to healthy control
Rag2/ and inflamed T cell transferred Rag2/mice. Although
no differences in systemic inflammatory parameters and colonic
inflammation were detected (Figures S5A and S5B), L.c feeding
significantly reduced cecal inflammation compared to the
feeding of lactocepin-deficient L.c prtPdis (Figure 5A and 5B).
The reduced cecal inflammation in L.c-fed mice correlated with
strongly reduced IP-10 tissue levels (Figure 5C) and significantly
reduced T cell infiltration into the cecal tissue (Figure 5D) com-
pared to the L.c prtPdis fed mice. It should be mentioned that
neither i.p. injection (Figures S3D and S3E) nor oral application
of lactocepin (Figure S5C) exerted negative effects on E-Cad-
herin, confirming the highly specific substrate profile of lactoce-
pin in vivo.
In order to support the assumption that the presence of prtP-
encoded lactocepin is the underlying cause for the observed
protective effects of L.c on cecal inflammation in T cell trans-
ferred RAG2/ mice, we performed monoassociation studies
with L.c and L.c prtPdis. Transcriptional analysis of cecum-
derived L.c revealed in vivo expression of prtP-encoded lactoce-
pin (Figure 5E). Although total bacterial numbers in the cecum
did not differ between L.c and L.c prtPdis-monoassociated
mice (Figure S5D), cecal water analysis revealed significantly
higher anti-IP-10-degrading capacity in L.c compared to L.c
prtPdis-monoassociated mice (Figure 5F). Furthermore,Inc.
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Figure 3. The Serine Protease in CM L.p Degrades Tissue-Distributed IP-10 Resulting in Physiologically Relevant Anti-Inflammatory Effects
in Inflamed Ileal Tissue of TNFDARE/+ Mice
(A) Terminal ileal specimen of TNFDARE/+ mice (n = 3) were incubated with CM L.p (33) or PMSF-pretreated CM L.p (33) for 24 hr. The concentration of TNF and
IP-10 in the explant supernatant was measured by ELISA. Data are presented as mean ± SD.
(B) Terminal ileal specimen of TNFDARE/+ mice (n = 3) were incubated with CM L.p (33) for 24 hr. IP-10 levels in the tissue were subsequently analyzed by western
blot analysis.
(C–E) Inflamed TNFDARE/+ mice (n = 3 per group) were i.p. injected (every 2nd day) with PBS or CM L.p (1503) for 3 weeks. The level of IP-10 and TNF (C) and
the level of phosphorylated NFlB, p38, and Akt (D) in the terminal ileal tissue were analyzed by western blot (samples were pooled per group). (E) Mononuclear
cell (MNC) infiltration into the muscularis of TNFDARE/+ mice was determined via counting MNC in the H&E-stained muscularis at three representative regions
of interest (roi) per mouse (E, upper panel). The level of T cell infiltration in the ileal tissue was determined by immunofluorescence staining of CD3+ cells followed
by CD3+ signal quantification using Volocity (E, middle and lower panel).
(F) Inflamed TNFDARE/+ mice were analogously i.p. injected with CM L.p (150x) or PMSF-inactivated CML.p (1503) andMNC infiltration into themuscularis (upper
panel), and T cell infiltration in the ileal tissue (middle and lower panels) was determined as described above. Depicted box plots represent 10th to 90th percentiles.
(*) indicates p values% 0.05; (**) indicates p values% 0.01. See also Figure S3.
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Protective Chemokine Degradation via Lactocepinsignificantly higher numbers of L.c were found to be attached to
the cecal mucosa compared to L.c prtPdis (Figure S5E). These
results indicate that active prtP-encoded lactocepin is ex-
pressed in close proximity to the cecal tissue, supporting our
hypothesis that the chemokine-degrading activity of prtP-
encoded lactocepin mediates the observed anti-inflammatory
effects on cecal inflammation in T cell transferred RAG2/mice.
DISCUSSION
PrtP-encoded lactocepin was identified to be the active micro-
bial structure underlying L.p-mediated loss of IP-10 and was
found to exert physiologically relevant anti-inflammatory effects
via selective degradation of an array of proinflammatory
chemokines.
Lactocepins comprise a broad group of cell envelope protein-
ases and are mainly expressed by lactococci and lactobacilli.
Depending on the respective species or even strain, lactococcal
and lactobacilli lactocepins are encoded by prtP, prtB, and/or
prtH. PrtP-encoded lactocepins are best known for their casein-
olytic properties and play an important role in the dairy industry.
In consequence, extensive research has already been per-Cell Hformed to clarify the highly complex maturation processes and
substrate specificities of prtP-encoded lactocepins. It is there-
fore known that although most prtP-encoded lactocepins show
very high sequence homology, the localization (cell-wall associ-
ated and/or secreted) and the specificity of lactocepin isoforms
is strain specific (Haandrikman et al., 1989; Haandrikman et al.,
1991; Holck and Naes, 1992). PrtP-encoded lactocepins are
divided into PI- and PIII-type proteinases according to their
caseinolytic substrate specificity (alphas1-, alphas2-, beta-, and
kappa-casein) and even subclassified with regard to their
preferred cleavage sites within alphas1-casein (Kunji et al.,
1996; Savijoki et al., 2006). However, the present study demon-
strates an anti-inflammatory impact of these long-known bacte-
rial proteases in the context of chronic inflammatory diseases
(Savijoki et al., 2006).
L.p was found to express very high amounts of prtP-encoded,
cell surface-associated and secreted lactocepin, showing an
unexpected anti-inflammatory substrate spectrum. The bacterial
protease was found to selectively degrade IP-10 and other
proinflammatory chemokines in vitro. In addition, prtP-encoded
lactocepin selectively degrades IP-10 in inflamed intestinal
tissue, showing that the protease retains its protective activityost & Microbe 11, 387–396, April 19, 2012 ª2012 Elsevier Inc. 391
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Figure 4. Identification of prtP-Encoded Lactocepin as the Active IP-10 Degrading Protease in CM L.p
(A) mIP-10 was coincubated with CM L.p or CM BL23 (24 hr). IP-10 concentration was subsequently measured by ELISA (upper panel). CM L.p and CM BL23
were subjected to LC-MS/MS analysis in order to identify the protein content (Table S1). The lower panel indicates the result of the LC-MS/MS analysis with
regard to the identification of prtP-encoded lactocepin. Spectral counts display the number of identified lactocepin peptides. Sequence coverage displays the
percentage of the prtP-sequence that is covered by the detected peptides. The localization of identified peptides within the lactocepin protein sequence is
presented using yellow and green (modified peptides) marks in the bar chart (C: C terminus, N: N terminus).
(B) shows the result of the immunoprecipitation of lactocepin using an anti-lactocepin antibody and protein A/G beads. IP-10 was incubated with lactocepin-
loaded beads or control beads (24 hr) and IP-10 concentration was subsequently determined via ELISA analysis (upper panel). The lactocepin-loaded beads and
the control beads were subjected to LC-MS/MS analysis (lower panel). LC-MS/MS results were presented as explained in (A).
(C) Immunoprecipitation of lactocepin as above, followed by exposure of the lactocepin-loaded beads to PMSF and coincubation with mIP-10. Subsequently,
IP-10 concentration was determined via ELISA analysis.
(D) mIP-10 was incubated with CM L.c (L.c = L.c BFLM 218 isolated from human feces), PMSF-inactivated CM L.c, CM L.p, or PMSF-inactivated CM L.p (24 hr).
IP-10 concentration was measured by ELISA.
(E) DNA of L.c and L.c prtPdis (= site targeted prtP disruption mutant of L.c) was isolated and subjected to PCR analysis using a primer pair specific for the
disrupted prtP gene. A primer pair spanning a region downstream the internal fragment was used as loading control.
(F) mIP-10 was incubated with CM L.c or CM L.c prtPdis (24 hr). IP-10 concentration was measured by ELISA (upper panel). CMs were subjected to LC-MS/MS
analysis and results are presented as explained in (A) (lower panel).
(G) mIP-10 was incubated with fixed (f) L.c or fL.c prtPdis (53 105 cells in 100 ml mIP-10) (24 hr), and IP-10 concentration was subsequently measured by ELISA.
Data are represented as mean ± SD. (*) indicates p values% 0.05; (**) indicates p values% 0.01. See also Figure S4 and Table S1.
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Protective Chemokine Degradation via Lactocepinin a physiological context. However, in contrast to other bacterial
proteases (Steck et al., 2011), prtP-encoded lactocepin neither
impaired IEC barrier function nor exerted adverse effects in vivo.
These findings confirm that prtP-encoded lactocepin is a highly
selective protease although it targets a broad spectrum of
cleavage sites, indicating that additional protein characteristics
like surface charge and/or the three dimensional structure
determine whether a protein is cleaved or not. Similar struc-
ture-dependent target recognition was proposed for the Group392 Cell Host & Microbe 11, 387–396, April 19, 2012 ª2012 ElsevierA streptococcal protease SpyCEP/ScpC, a PrtS-encoded lacto-
cepin family member that selectively degrades IL-8, KC, and
MIP-2, and was therefore shown to be an important virulence
factor of this pathogen (Edwards et al., 2005; Hidalgo-Grass
et al., 2006; Kaur et al., 2010; Zinkernagel et al., 2008). However,
in the case of otherwise harmless bacteria such as L.p (Ewa-
schuk et al., 2007), selective degradation of proinflammatory
chemokines like IP-10, I-TAC, and Eotaxin by prtP-encoded lac-
tocepin constitutes rather a potent anti-inflammatory trait in theInc.
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Figure 5. The Cecal Expression of Active prtP-Encoded Lactocepin Correlates with Significantly Reduced Cecal Inflammation
(A–D) Control and T cell transferred Rag2/mice were fed L.c BFLM 218 (L.c) or its isogenic lactocepin-deficient mutant L.c prtPdis for 4 weeks starting 6 weeks
after T cell transfer. (A) shows representative H&E staining of cecal segments, and (B) shows the result of the histopathological scoring of the cecum. (C) shows
representative immunofluorescence stainings of IP-10 (green), b-catenin (red), and DAPI (blue) in the cecal tissue. (D) shows representative stainings of CD3
(green) and DAPI (blue) and the mean intensity of the CD3 signal in the cecal tissue. Depicted box plots represent 10th to 90th percentiles.
(E and F) Wild-type mice were monoassociated with either L.c or L.c prtPdis. (E) shows prtP-specific PCR analysis of mRNA isolated from L.c and L.c prtPdis
residing in the cecum of monoassociated mice. In (F), IP-10 was incubated with cecal water from L.c and L.c prtPdis-monoassociated mice (24 hr), and IP-10
concentration was subsequently determined via ELISA. Data are represented asmean ± SD. (*) indicates p values% 0.05; (**) indicates p values% 0.01. See also
Figure S5.
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Protective Chemokine Degradation via Lactocepincontext of IBD and other chronic inflammatory diseases. Indeed,
our proof of concept study in TNFDARE/+ mice supports the
hypothesis that lactocepin-mediated chemokine degradation
mediates physiologically relevant anti-inflammatory effects.
However, in contrast to the direct application of active prtP-
encoded lactocepin, the potential anti-inflammatory effect of
orally applied lactocepin-expressing bacteria is strongly depen-
dent on the location and level of lactocepin secretion in the
intestine. Oral uptake of prtP-encoding L.c resulted in a potent,
but intestinal site-specific, anti-inflammatory effect in T cell
transferred Rag2/ mice, demonstrated by strongly reduced
levels of IP-10, significantly reduced T cell infiltration, and signif-
icantly reduced cecal inflammation compared to mice that were
fed lactocepin-deficient L.c prtPdis. Subsequent monoassocia-
tion studies with L.c and L.c prtPdis followed by transcriptional
analysis of cecal bacteria proved that L.c does express prtP-
encoded lactocepin in the cecum of monoassociated mice.
Consistently, cecal water of L.c monoassociated mice showed
significantly higher IP-10-degrading activity compared to theCell Hcecal water derived from L.c prtPdis monoassociated mice.
Furthermore, the number of L.c attached to the cecal mucosa
was found to be significantly higher compared to L.c prtPdis,
although the number of lumenal cecal bacteria was comparable.
In summary, these findings indicate that the protective effect of
L.c on cecal inflammation in the adoptive transfer model is due
to the expression of active prtP-encoded lactocepin in close
proximity to the cecal tissue. Despite the potent anti-inflamma-
tory effect of prtP-encoded lactocepin on cecal inflammation,
the inflammation of the distal colon was similar in L.c-fed and
L.c prtPdis-fed T cell transferred RAG2/ mice. The reason for
this discrepancy is unclear but might be due to different ex-
pression, activity, or target site accessibility of prtP-encoded
lactocepin in different intestinal compartments. Of note, site-
specific protection of the cecum by lactocepin-expressing L.c
mimics our previous findings in VSL#3-fed IL10/ mice (Ho¨r-
mannsperger et al., 2009).
Although many lactobacilli and lactococci are known to
encode prtP, only few bacterial strains were found to exertost & Microbe 11, 387–396, April 19, 2012 ª2012 Elsevier Inc. 393
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compared to L.p. The underlying reasons might include differ-
ences in the regulation of prtP expression, variation in prtP
expression levels, or strain-specific substrate profiles of the
bacterial protease. Indeed, BL23, like the active fecal isolate
L.c, encodes a lactocepin that is 99% homologous to L.p prtP.
However, BL23 does not express the protease in CM (Figure 4A),
although we found it to express lactocepin in milk, showing that
the expression of prtP is regulated by environmental factors.
Furthermore, CM PHa (Broadbent et al., 2002) does not show
anti-IP-10 activity despite the presence of proteolytically active
(casein-degrading) lactocepin, which is 98% homologous
to L.p prtP, demonstrating different substrate profiles of PHa-
versus L.p-produced prtP-encoded lactocepin. These highly
diverse expression profiles and substrate specificities of prtP-
encoded lactocepins from different lactococci and lactobacilli
are of great relevance for the potential anti-inflammatory effects
of the respective strains, but the molecular mechanism under-
lying these differences remain to be determined.
In summary, the selective degradation of proinflammatory
chemokines by prtP-encoded lactocepin was identified as a
physiologically relevant anti-inflammatory microbial structure-
function relationship. Direct application of active prtP-encoded
lactocepin or oral uptake of lactocepin-expressing bacteria
might therefore exert potent anti-inflammatory effects not only
in IBD but also in the context of other chronic inflammatory
diseases, including allergic eczema (Menzies-Gow et al.,
2002), psoriasis (Chen et al., 2010), and rheumatoid arthritis
(Hueber et al., 2007; Lacotte et al., 2009).
EXPERIMENTAL PROCEDURES
Bacterial Culture and Preparation of Conditioned Media
L. paracasei VSL#3 (L.p) (classified as L. casei until 2009) (a generous gift from
Claudio De Simone, L’Aquila, Italy), L. paracasei BL23 (BL23) (Acedo-Fe´lix and
Pe´rez-Martı´nez, 2003) and BL23 prtPdis (prtP-disruption mutant), L. casei
BFLM 218 (L.c) (isolated of human feces; institute-internal classification) and
L.c prtPdis (prtP-disruption mutant) were anaerobically grown at 37C in
MRS broth (Fluka, Heidelberg, Germany) containing 0.05% L-cysteine
(Roth). For the culture of L.c prtPdis, erythromycin (5 mg/ml) was added. Fixed
bacteria (5% formaldehyde, 3 hr, 4C) were washed 33 with sterile PBS
(Invitrogen, Carlsbad, CA) before use. To generate conditioned media (CM),
bacteria (13: 5 3 107 cfu/ml) from an o.n. culture were transferred to Dulbec-
co’s modified Eagle’s medium (DMEM) (1% glutamine [Invitrogen, Carlsbad,
CA], 20 mM HEPES [Invitrogen, Carlsbad, CA]) and cultivated anaerobically
(o.n., 37C). Bacteria and CM were separated via centrifugation (4300 g,
15 min, RT). CM was adjusted to pH 7.6, filter sterilized (0.22 mm), diafiltrated
in PBS, and concentrated using Vivacell filter systems (exclusion size:
100 kDa, satorius stedim biotech, Goettingen, Germany). Serine protease
inhibition was achieved by adding phenylmethylsulfonylfluoride (PMSF)
(2 mM) to CM L.p, and free PMSF was removed via PBS diafiltration for in vivo
experiments. Matrix metalloproteases were inhibited by Marimastat (Marim.)
(0.5 mM) (Tocris Bioscience, Ellisville, MO).
Cell Culture
The small intestinal epithelial cell line Mode-K (passage 10–25) was grown in
DMEM (GIBCO Invitrogen, Carlsbad, CA), 10% FCS (FCS Superior; Biochrom,
Berlin, Germany), 1.0% glutamine, and 0.8% antibiotic antimycotic (GIBCO
Invitrogen, Carlsbad, CA) in Cellstar tissue culture flasks (Greiner Bio-One,
Frickenhausen, Germany) (5% CO2, 37
C). Stimulation experiments were
performed in 12-well NunclonD Surface plates (Nunc, Roskilde, Denmark)
(80% confluency) using tumor necrosis factor (TNF) (10 ng/ml) (R&D Systems,
Wiesbaden-Nordenstadt, Germany) and/or concentrated CM (diluted to 13).394 Cell Host & Microbe 11, 387–396, April 19, 2012 ª2012 ElsevierELISA
IP-10, TNF, and IL-6 concentrations were analyzed using the appropriate
ELISA kits (R&D Systems, Wiesbaden-Nordenstadt, Germany).
Western Blot Analysis
Ileal tissue or Mode-K cells were lysed in 1 3 Laemmli buffer, protein was
isolated and 20 mg of protein was subjected to electrophoresis. Anti-IP-10,
anti-TNF (R&D, Wiesbaden-Nordenstadt, Germany), anti-p-p38, anti-pAkt,
anti-pRelA (New England Biolabs, Frankfurt, Germany), and anti-b-actin
(MP Biomedicals, Illkirch, France) were used to detect the respective proteins
using an enhanced chemiluminescence light-detecting kit (Amersham,
Arlington Heights, IL).
Immunofluorescence Staining
Immunofluorescence analysis was performed to stain IP-10 (anti-IP-10
sc-1406), E-Cadherin (Santa Cruz, Heidelberg, Germany), CD3 (Abcam,
Cambridge, UK), myeloperoxidase (MPO) (Thermo Fisher Scientific, Schwerte,
Germany), and b-catenin (#9587S) (New England Biolabs, Frankfurt, Germany)
in paraffin-embedded tissue sections. Antigen-unmasking was performed by
cooking in sodium citrate buffer (10 mM, pH6). Confocal microscopy was
performed using an Olympus BX61 confocal microscope (Olympus, Hamburg,
Germany). Quantification of CD3-positive cells, MPO-positive cells, and
E-Cadherin was performed using Volocity 3D Image Analysis Software. The
level of CD3, MPO, or E-Cadherin was quantified via determination of the
intensity of the respective signal at three representative regions of interest
(roi) per mouse (roi = rectangle of 40,000 mm2).
Cleavage Assays
We incubated 0.5 ml CM L.p (2003) with 250 ng of the respective recombinant
protein of interest (1 hr or 24 hr) (murine [m] IP-10, human [h] IP10, mSDF-1a,
hSDF-1a, mI-TAC, hI-TAC, mCXCL1, m CXCL5, hFractalkine, hEotaxin,
mMIG, mGROb, mRANTES, hMIP-3a, mMIP-2, hIL-8, mIL-6, hGCP, mTNF,
hTNF (all purchased from PeproTech, Hamburg, Germany), mIFNg (Initrogen,
Carlsbad, CA), mIL-10 (R&D Systems, Wiesbaden-Nordenstadt, Germany),
mE-Cadherin or hE-Cadherin (both Leinco, St. Louis, MO). Subsequent
MALDI-TOF analysis was performed according to the Supplemental Informa-
tion. For SDS-Page analysis, samples were mixed with 5 ml of 13 Laemmli
buffer. The gel was fixed (40% ethanol, 10% acetic acid, 1 hr), stained for
1 hr in 13 Flamingo (BioRad, Hercules, CA), and the protein was visualized
(Typhoon Trio+ variable mode imager, GE Healthcare Life Sciences, Chalfon
St. Giles, UK).
Immunoprecipitation
CM L.p VSL#3 (1503) was incubated with and without anti-lactocepin anti-
bodies directed against a lactococcal lactocepin (kindly provided by Harry
Laan, Menz Engineering, Netherlands; Laan et al. [1988]) (3 hr, 4C) in a shaker.
Samples were then incubated with protein A/G beads (Santa Cruz, Europe)
(o.n., 4C) in a shaker. Beads were separated from CM (2 min, 8000 g) and
washed (43, 1 ml 13 PBS). The IP-10-degrading capacity of the beads was
subsequently determined via an o.n. incubation step (37C) followed by ELISA.
The beads were washed (43, 1ml 13 PBS), resuspended (20 ml, 13 PBS),
heated (95C, 15 min), and the supernatant was analyzed via LC-MS/MS
analysis.
Animal Trials
Wild-type mice (wt) (background: C57BL/6) and heterozygous TNFDARE/+ mice
(Kontoyiannis et al., 1999) (background: C57BL/6; a generous gift from Kollias,
G., Institute for Immunology, Biomedical Sciences Research Center ‘‘Alex-
ander Fleming,’’ Vari/Athens, Greece) were conventionally raised on ssniff
R/M-H diet (ssniff, Soest, Germany). Rag2/ mice were raised under SPF
conditions. Inflamed heterozygous TNFDARE/+ mice (8 weeks) (n = 6) got i.p.
injections of CM L.p or PBS every second day for 3 weeks. In a second
experimental setup, inflamed heterozygous TNFDARE/+ mice (9 weeks) (n = 6)
got analogous i.p. injections of CML.p or PMSF-inhibited CM.Mice were killed
by cervical dislocation and ileal tissue was removed for protein isolation, H&E
staining, and the determination of immune cell infiltration. Rag2/ mice were
i.p. injected with 5 3 105 CD4+IL10/ splenic T cells. From 6 weeks until
10 weeks after the transfer, transferred and control Rag2/ mice (n = 5 perInc.
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At week 10 after the transfer, all Rag2/ mice were killed by CO2. Animal
experiments were performed as approved by the institution in charge (animal
trial application no. 55.2-1-54-2531-88-09). Germ-free BALB/c-mice were
monoassociated with a single gavage of 1 3 108 cfu L.c or L.c prtPdis (n = 5
per group). Ten days after the initial bacterial exposure the mice were killed
by cervical dislocation and cecal samples for the determination of lumenal/
mucosally attached bacteria and the analysis of lumenal prtP expression
were obtained. The experiments were approved by the institutional animal
care and use committee at the Academy of Sciences of the Czech Republic
(approval no. 9890/2009-17210).
Ileal Explant Culture
0.5 cm sections were taken from the terminal ileum of 14- to 16-week-old wt
(n = 3) and TNFDARE/+ mice (n = 3). The opened gut was placedwith the lumenal
side to the top on a netwell polyester membrane (500 mmmash size) (Corning,
Corning, NY) and incubated in basolateral contact with the respective medium
(o.n.). Protein was subsequently isolated via mashing the ileal explant in 100 ml
lysis buffer (7 M urea, 2 M thiourea, 2% CHAPS, 1% DTT [Roth, Karlsruhe,
Germany], cOmplete mini and PhosSTOP [Roche Diagnostics, Mannheim,
Germany]) followed by homogenization (10 ultrasonic pulses, cycle 0.5,
amplitude 80) and centrifugation (18,000 g, 20 min). The supernatant was
taken for protein quantification.
Histopathological Analysis
Tissue sections were fixed in 10% neutral buffered formalin, dehydrated, and
paraffin-embedded, and tissue slides (5 mm) were deparaffinized and H&E-
stained. Histopathological scores were determined by a blinded and indepen-
dent pathologist using an established scoring system (score from 0–12)
(Katakura et al., 2005). The number of infiltrated MNC in the muscularis of
TNFDARE/+ mice was determined via counting all MNC in the H&E stained
muscularis at three representative roi per mouse (roi = rectangles with a
baseline of 100 mm).
Protein Identification by Liquid Chromatography-Tandem Mass
Spectrometry (LC-MS/MS)
Samples were analyzed via LC-MS/MS analysis as described in the Supple-
mental Experimental Procedures.
Site-Targeted Disruption of prtP (prtPdis)
For prtP gene disruption, an internal fragment (484 bp) of prtP from BL23
(see Supplemental Experimental Procedures for sequence) was cloned into
the integrative and erythromycin resistance coding vector pRV300 at the
pBluescript polylinker (between EcoRI and SacI) (Leloup et al., 1997) using
Escherichia coliDH5a (grown inM17medium, 0,5%glucose, 100mg/ml ampi-
cillin) as cloning host (generous gift from Vincente Monedero, Instituto de
Agroquimica y Tecnologı´a de Alimentos, Valencia, Spain). The vector was iso-
lated using the DNA purification system Wizard Plus, SV MiniPrep (Promega,
Madison, WI). Electrocompetent cells were obtained as described (Posno
et al., 1991), transformed with the prtP-disruption construct and plated on
MRS plates supplemented with erythromycin. Erythromycin-resistant colonies
were picked and chromosomal DNA was isolated using DNeasy Blood &
Tissue Kit (QIAGEN, Hilden, Germany). Integration of the vector at the correct
locus was verified by PCR on chromosomal DNA isolated from erythromycin-
resistant colonies using primers as specified in the Supplemental Experimental
Procedures.
Cecal Water Activity
Cecal content of mice monoassociated with L.c or L.c prtPdis was resus-
pended in sterile 13 PBS (w/v = 100 mg/ml). Cecal water was separated
from nutrient debris and bacteria via centrifugation (10min, 5000 g) and subse-
quently incubated with IP-10 (o.n., 37C, dilution 1:500). The remaining IP-10
concentration was determined via ELISA analysis.
Determination of prtP mRNA Expression In Vivo
Cecal gut content of L.c or L.c prtPdis-monoassociated BALB/c-mice was
resuspended in sterile 13 PBS (w/v = 100 mg/ml). The suspension was first
purged from nutrient debris (3 min, 350 g) and cecal gut content-derivedCell Hbacteria were obtained by subsequent centrifugation (5 min, 5000 g). Bacterial
cells were lysed via incubation with lysozyme (2 mg/ml), mutanolysin (10 units
per sample) (15 min). Total RNA was isolated using the NucleoSpin RNA kit
(Macherey-Nagel, Du¨ren, Germany).
Statistics
Statistical tests were performed using Sigma Plot 11.0 software. Data com-
paring two or more groups/treatments were analyzed with unpaired Student’s
t test, one-way analysis of variance, or two-way analysis of variance. Differ-
ences were considered significant if p values were < 0.05 (*) or < 0.01 (**).
Data depicted in bar charts are expressed as mean values ± SD. Data repre-
sented in box plots are expressed as 10th to 90th percentiles.ACCESSION NUMBERS
The nucleic acid sequence of L.p prtP and L.c prtP have been deposited at
GenBank database and can be retrieved by the respective accession
numbers: L.p prtP, JQ625054; L.c prtP, JQ625055.
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